Researchers Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, in 2003 obtained a patent Pentagamavunon-0 in the United States, which is a modified curcumin compound inhibiting cancer cells. Chitosan nanoparticles now being developed to bring curcumin to more effectively target the cancer cells.
This (modified curcumin) to anticancer drugs in combination with curcumin in the overlying chitosan nanoparticle size, "says lecturer and researcher at the Faculty of Pharmacy, Gadjah Mada University, Ronny Martien, Thursday (23 / 6), after receiving the award and research grant from the Bureau Oktroi and the Indonesian Academy of Sciences (AIPI) in Jakarta.
Ronny is one of four other young researchers who were given grants by the Bureau of research and AIPI Oktroi. Ronny proposed field of research utilization on Biological Diversity.
Research title "Utilization of Chitosan in Improving Bioavailibilitas Compound Pentagamavunon-0 (PGV-0) as an Analgesic-antiinflammatory drugs with formulations of Nanoparticles".
PGV-0 is a derivative of an analog of curcumin derived from turmeric and ginger rhizome. According to Ronny, PGV-0 studied GMU in cooperation with the Dutch.
